SCHEMBL529112

SCHEMBL529112

CCOC(=O)c1cnc2ccc(Cl)cc2c1Nc1ccc(N)cc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.81
GAA P10253 7/20 0.70
HTT P42858 3/20 0.69
ALDH1A1 P00352 1/20 0.69
MEN1 O00255 3/20 0.63
KMT2A Q03164 3/20 0.63
KDM4E B2RXH2 1/20 0.63
SMN1; SMN2 Q16637 7/20 0.62
TP53 P04637 4/20 0.62
PAX8 Q06710 1/20 0.62
THRB P10828 1/20 0.59
LMNA P02545 3/20 0.57
MC4R P32245 2/20 0.57
TDP1 Q9NUW8 2/20 0.57
L3MBTL1 Q9Y468 2/20 0.57
NPSR1 Q6W5P4 2/20 0.57
PTK2B Q14289 1/20 0.57
MAPK1 P28482 1/20 0.56
CLK1 P49759 1/20 0.56
GSK3A P49840 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23575213 0.89 MAPT (0.81) MAPTGAAHTTALDH1A1MEN1
SCHEMBL528932 0.89 MAPT (0.80) MAPTGAAHTTALDH1A1MEN1
SCHEMBL23575645 0.88 MAPT (0.76) MAPTGAAHTTALDH1A1MEN1
SCHEMBL529473 0.88 MAPT (0.78) MAPTGAAHTTALDH1A1MEN1
SCHEMBL1369529 0.86 MAPT (0.75) MAPTGAAHTTALDH1A1MEN1
SCHEMBL3787191 0.85 MAPT (0.74) MAPTGAAHTTALDH1A1MEN1
SCHEMBL8884082 0.84 MAPT (0.72) MAPTGAAHTTALDH1A1MEN1
SCHEMBL27907345 0.83 MAPT (0.56) MAPTGAAHTTALDH1A1PAX8
SCHEMBL3790489 0.83 MAPT (0.71) MAPTGAAHTTALDH1A1MEN1
SCHEMBL15334759 0.82 MAPT (0.69) MAPTGAAHTTALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9120749-B2 Quinoline derivatives and MELK inhibitors containing the same ONCOTHERAPY SCIENCE, INC. (JP) 2015-09-01 US disclosed
US-9120749-B2 Quinoline derivatives and MELK inhibitors containing the same ONCOTHERAPY SCIENCE, INC. (JP) 2015-09-01 US disclosed
US-9120749-B2 Quinoline derivatives and MELK inhibitors containing the same ONCOTHERAPY SCIENCE, INC. (JP) 2015-09-01 US disclosed
US-20130217671-A1 QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME ONCOTHERAPY SCIENCE, INC. (JP) 2013-08-22 US disclosed
US-20130217671-A1 QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME ONCOTHERAPY SCIENCE, INC. (JP) 2013-08-22 US disclosed
US-20130217671-A1 QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME ONCOTHERAPY SCIENCE, INC. (JP) 2013-08-22 US disclosed
EP-2597955-A1 QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME OncoTherapy Science, Inc. (JP) 2013-06-05 EP disclosed
WO-2012016082-A1 QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME ONCOTHERAPY SCIENCE, INC. (JP) 2012-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217671-A1 QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME MELK, NADK, NEK1 MAPT 2791/4885GAA 2876/4885HTT 2716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.